StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc.

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.33−0.35 (-0.21%)

Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%

Gilead Sciences Veklury (remdesivir by Quarter

Veklury (remdesivir — COVID-19 antiviral) — U.S. sales ($M) ($M)

QuarterlyAnnual

Gilead Sciences Veklury (remdesivir: $14M in Q2 2026, down 72.5% from a year earlier.

Latest, Q2 2026
14
Period ended Jun 30, 2026
Change on a year earlier
-72.5%
51 in Q2 2025
History
28 quarters
Since Q3 2019
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

Source: Form 10-Q (filed 2026-08-06) ↗

Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedVeklury (remdesivir — COVID-19 antiviral) — U.S. sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 202614-72.5%Form 10-Q (filed 2026-08-06) ↗
Q1 2026Mar 31, 2026112-43.7%Form 10-Q (filed 2026-05-07) ↗
Q4 2025Dec 31, 202580-25.9%Form 10-K (filed 2026-02-24) ↗
Q3 2025Sep 30, 2025140-64.4%Form 10-Q (filed 2025-11-07) ↗
Q2 2025Jun 30, 202551-32.9%Form 10-Q (filed 2026-08-06) ↗
Q1 2025Mar 31, 2025199-36.8%Form 10-Q (filed 2026-05-07) ↗
Q4 2024Dec 31, 2024108-70.4%Form 10-K (filed 2026-02-24) ↗
Q3 2024Sep 30, 2024393+52.3%Form 10-Q (filed 2025-11-07) ↗
Q2 2024Jun 30, 202476-21.6%Form 10-Q (filed 2025-08-07) ↗
Q1 2024Mar 31, 2024315+25.0%Form 10-Q (filed 2025-05-07) ↗
Q4 2023Dec 31, 2023365-7.8%Form 10-K (filed 2026-02-24) ↗
Q3 2023Sep 30, 2023258-23.2%Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 202397+136.6%Form 10-Q (filed 2024-08-08) ↗
Q1 2023Mar 31, 2023252-68.5%Form 10-Q (filed 2024-05-08) ↗
Q4 2022Dec 31, 2022396-54.8%Form 10-K (filed 2025-02-28) ↗
Q3 2022Sep 30, 2022336-78.0%Form 10-Q (filed 2023-11-07) ↗

Cite this data

StockData. (2026). Gilead Sciences Veklury (remdesivir ($M), quarterly Q3 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/veklury-total-us

See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.